Partnership between Paradigm4 and Alnylam accelerates drug target discovery
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets…
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets…
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development.…
As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit…
US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug -- for treatment…
Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to…
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal…
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
Now that we've got the bad news out of the way, we're here to spread…
Everything you need to know about what RNAi is, how it works and how it…
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA?…
Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi…
Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy…